Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics is viewed favorably because its lead IGF-1R antagonist Lumvoa has already shown differentiated efficacy in active and chronic TED, with pivotal THRIVE and THRIVE-2 data meeting all primary and secondary endpoints and supporting best-in-class potential versus Tepezza. Early commercial evidence is also encouraging, as management reached 95% of the ~2,000 core prescribers contacted, while KOLs reported early prescriptions, infusions within 88 days of launch, and relatively smooth payer access despite near-term formulary and J-code friction. The broader platform adds further upside through elegrobart’s 43-day half-life, 5 versus 8 infusion convenience, and a pipeline that could help build a durable AMGN/VRDN duopoly in TED.

Viridian Therapeutics is facing a structurally challenged TED market where anti-IGF1R drugs are valued for broad symptom control but are increasingly constrained by patient fear of hearing loss and physician concern about recurrence, limiting conversion even among eligible patients. The excerpts show only about 1–2 of 8–10 candidates at one practice and roughly 1 prescription per month at another, with recurrence rates cited around 10–20% or even near-universal in some cohorts, which undermines the durability story for veligrotug and elegrobart. Fundamentally, the company also remains a clinical-stage, capital-intensive biopharma with late-stage regulatory and commercial execution risk, while Tepezza’s 6–7 year head start and Amgen’s resources raise the bar for meaningful market share.